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cAMP signaling plays a key role in regulating pain sensitivity. Here,
we uncover a previously unidentified molecular mechanism in which
direct phosphorylation of the exchange protein directly activated by
cAMP 1 (EPAC1) by G protein kinase 2 (GRK2) suppresses Epac1-to-Rap1
signaling, thereby inhibiting persistent inflammatory pain. Epac1−/−
mice are protected against inflammatory hyperalgesia in the com-
plete Freund’s adjuvant (CFA) model. Moreover, the Epac-specific
inhibitor ESI-09 inhibits established CFA-induced mechanical hyperal-
gesia without affecting normal mechanical sensitivity. At the mecha-
nistic level, CFA increased activity of the Epac target Rap1 in dorsal
root ganglia of WT, but not of Epac1−/−, mice. Using sensory neuron-
specific overexpression of GRK2 or its kinase-dead mutant in vivo, we
demonstrate that GRK2 inhibits CFA-induced hyperalgesia in a kinase
activity-dependent manner. In vitro, GRK2 inhibits Epac1-to-Rap1
signaling by phosphorylation of Epac1 at Ser-108 in the Dishev-
eled/Egl-10/pleckstrin domain. This phosphorylation event inhibits
agonist-induced translocation of Epac1 to the plasma membrane,
thereby reducing Rap1 activation. Finally, we show that GRK2 in-
hibits Epac1-mediated sensitization of the mechanosensor Piezo2
and that Piezo2 contributes to inflammatory mechanical hyperal-
gesia. Collectively, these findings identify a key role of Epac1 in
chronic inflammatory pain and a molecular mechanism for control-
ling Epac1 activity and chronic pain through phosphorylation of
Epac1 at Ser-108. Importantly, using the Epac inhibitor ESI-09, we
validate Epac1 as a potential therapeutic target for chronic pain.
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Today >116 million adults in the United States are affected bychronic pain (1), which is accompanied by disability, de-
pression, and reduced quality of life. Chronic pain is associated
with multiple inflammatory conditions, such as rheumatoid ar-
thritis, inflammatory bowel disease, osteoarthritis, and postsurgical
inflammation (1). Inflammatory mediators (including PGE2, sub-
stance P, bradykinin, ATP, and IL-1β) act on primary sensory
neurons (nociceptors) and alter the excitability of nociceptors via
transcriptional and/or posttranslational mechanisms to cause pain
hypersensitivity (hyperalgesia). cAMP signaling plays a key role in
pain signaling, and mice deficient in adenylate cyclase activity are
protected against inflammatory pain (2, 3). The contribution of the
cAMP sensor protein kinase A (PKA) to inflammatory pain has
been described extensively (3–5). Exchange protein directly ac-
tivated by cAMP 1 (Epac1) is a more recently discovered effector
of cAMP signaling. The first evidence for a role of Epac1 signaling
in pain came from Levine and coworkers, who reported that
intraplantar injection of the Epac agonist 8-(4-chlorophenylthio)-
2′-O-methyl-cAMP (8-pCPT) leads to long-lasting mechanical
hyperalgesia (6). More recent evidence shows that Epac1−/−
mice are protected against development of chronic neuropathic
pain (7), but it is not known whether Epac1 is also required for
inflammatory pain.
Epac1 is a guanine nucleotide exchange factor (GEF) cata-
lyzing the exchange of GDP for GTP for the Ras-like GTPases
Rap1 and Rap2, resulting in their activation (8–10). Subcellular
localization of Epac1 is dynamic and spatiotemporally regulated.
In cells, agonist stimulation induces rapid translocation of cy-
tosolic Epac1 to the plasma membrane (PM), where it binds
phosphatidic acid (PA) via its Disheveled/Egl-10/pleckstrin
(DEP) domain and activates a local Rap1 pool (11, 12). In vitro
it has been shown that activated Rap signals to, e.g., Akt (13),
PLC-e (14), PKC, and MAPKs (15). Our recently published work
showed that the serine–threonine kinase G protein-coupled re-
ceptor kinase 2 (GRK2) inhibits Epac1-mediated pain signaling
(16, 17). Specifically, we showed that chronic inflammatory pain
is associated with a decrease in GRK2 levels in pain-sensing
neurons and that either increasing GRK2 protein levels or re-
ducing Epac1 levels prevents chronic pain (17). However, the
mechanism via which GRK2 controls Epac1-mediated pain sig-
naling remained to be identified. Here we demonstrate that
Epac1 is required for inflammation-induced mechanical hyperalgesia
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show that Epac1-dependent mechanical hyperalgesia is associated
with increased activation of its target Rap1 in dorsal root ganglia
(DRG). Moreover, we unveil a previously unidentified molecular
mechanism for controlling Epac1 activity and chronic pain through
GRK2-mediated phosphorylation of Ser-108 in Epac1, leading to
inhibition of Epac1-to-Rap1 signaling. GRK2 also inhibits Epac1-
mediated sensitization of the mechanosensitive channel Piezo2,
and in vivo, reducing Piezo2 inhibits inflammatory mechanical
hyperalgesia. Moreover, we demonstrate that the Epac inhibitor
ESI-09 treats chronic inflammatory pain.
Results
Complete Freund’s Adjuvant-Induced Mechanical Hyperalgesia Is
Dependent on Epac1 and Is Associated with Rap1 Activation. We
first assessed the role of Epac1 in inflammatory hyperalgesia. We
show that Epac1−/− mice are fully protected against development
of complete Freund’s adjuvant (CFA)-induced mechanical hyper-
algesia (Fig. 1A). CFA-induced thermal hyperalgesia and baseline
mechanical and thermal sensitivity were not affected by genetic
deletion of Epac1 (Fig. S1) (7).
Underlining the key role of Epac1 in persistent inflammatory
mechanical hyperalgesia, the competitive Epac-inhibitor ESI-09
dose-dependently inhibited already-established mechanical hyper-
algesia in a dose- and time-dependent manner (Fig. 1B) without
affecting mechanical sensitivity of control mice (Fig. S2). In line
with our data in Epac1−/−mice, ESI-09 did not affect CFA-induced
heat hyperalgesia (Fig. S2) or baseline heat sensitivity (Fig. S2).
ESI-09 also did not influence CFA-induced paw edema or gran-
ulocyte infiltration (Fig. S3).
Epac1 is a GEF for the small GTPase Rap1. The results in Fig.
1 show that in vivo CFA increases Rap1–GTP levels in the DRG
of WT mice, but not in Epac1−/− mice (Fig. 1C). Collectively,
these findings indicate that Epac1 is required for CFA-induced
inflammatory hyperalgesia and that the Epac1-to-Rap1 signaling
pathway is operative in nociceptors.
GRK2 Kinase Activity Inhibits Epac1-Dependent Inflammatory Hyperalgesia
and Epac1 Signaling to Rap1. To determine whether GRK2 regulates
Epac1-dependent inflammatory mechanical hyperalgesia in a
kinase-activity dependent manner, we used herpes simplex virus
(HSV) amplicons to overexpress GRK2 or the kinase-dead
mutant GRK2–K220R. Intraplantar injection of HSV–GRK2
reduced CFA-induced hyperalgesia, demonstrating that GRK2
regulates Epac1-dependent inflammatory mechanical hyperalgesia
(Fig. 2A). Injection of HSV–GRK2–K220R did not have any effect
on the mechanical hyperalgesia, indicating the requirement of
GRK2 kinase-activity for inhibiting inflammatory pain. Both
constructs induced a similar increase in GRK2 levels in DRG
neurons (Fig. S4).
Next, we assessed whether GRK2 kinase activity inhibits Rap1
activation in response to the Epac1 agonist 8-pCPT using a
Rap1–GTP pull-down assay with the human Ral GDS–Rap
binding domain (18). GRK2 overexpression in HEK cells or in
the neuronal cell line Neuro2a (N2A) inhibited Epac1-to-Rap1
signaling (Fig. 2 B and C), whereas overexpression of the kinase-
dead mutant GRK2–K220R did not affect Epac1-to-Rap1 sig-
naling (Fig. 2D).
GRK2 Phosphorylates Epac1 at Residue Ser-108 to Inhibit Rap1
Activation. Using pull-down analysis and live cell imaging, we
show that in cells, GRK2 and Epac1 are part of the same protein
complex and the interaction is mediated by the kinase domain of
GRK2 (Fig. S5). Moreover, PM tethering of GRK2 using mcherry-
tagged geranyl-geranyl-GRK2 (GRK2gg) recruited YFP–Epac1 to
the PM (Fig. S5).
An in vitro kinase assay with GRK2 and GST–Epac1 protein
showed that GRK2 phosphorylates Epac1 with a Km of ∼77 nM
(Fig. 3 A and B; Fig. S6). Phosphorylation of Epac1 was abol-
ished in the presence of heparin, a known inhibitor of GRK2
kinase activity that is frequently used in vitro for this purpose (19,
20) (Fig. 3A). Mass spectrometry analysis of Epac1 phosphorylated
Fig. 1. Role of Epac1 in mechanical hyperalgesia. (A) CFA-induced me-
chanical hyperalgesia in WT (n = 6) and Epac1−/− (n = 10) mice. Changes in
50% paw withdrawal threshold were monitored over time. Repeated-mea-
sures two-way ANOVA genotype effect: P < 0.0001. **P < 0.01 (post hoc
Bonferroni analysis). (B) Dose–response curve for the effect of ESI-09 (5, 20,
or 50 mg/kg) on CFA-induced mechanical hyperalgesia in WT mice (n = 8).
Treatment was started on the third day after CFA administration. *P < 0.05;
**P < 0.01 (50 mg/kg ESI-09 compared with the vehicle-treated mice); ***P <
0.001; ****P < 0.0001; ##P < 0.01 (20 mg/kg ESI-09 compared with the vehicle-
treated mice); ####P < 0.0001. (C) Rap1 activation in lumbar DRG of WT and
Epac1−/−mice 5 d after CFA administration. Results are means ± SEM of at least
three independent experiments. *P < 0.05 (t test); ns, not significant.
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by GRK2 in vitro identified Ser-108 in the DEP domain of hu-
man Epac1 as a putative GRK2 phosphorylation site (Fig. 3C
and Fig. S7). Phosphorylation of Ser-108 in Epac1, a conserved
residue across species (Fig. 3C), was also detected in N2A cells
overexpressing both GRK2 and Epac1, underlining its physio-
logical relevance. Mutation of Ser-108 to alanine inhibited the
ability of GRK2 to phosphorylate Epac1 in vitro by ∼50%, in-
dicating that this serine residue is the major GRK2 phosphory-
lation site in Epac1 (Fig. 3D).
Mutation of Ser-108 to alanine, which precludes phosphory-
lation of the residue by GRK2, prevented GRK2-mediated in-
hibition of Rap1 activation (Fig. 3E). Conversely, 8-pCPT–
induced Rap1 activation was reduced in N2A cells expressing a
phospho-mimic for Ser108, S108E (Fig. 3E). Collectively, the
data suggest that in cells overexpressing GRK2, phosphorylation
of Epac1 at Ser-108 underlies the inhibition of 8-pCPT–induced
Rap1 activation.
Phosphorylation of Epac1 at Ser-108 Inhibits Rap1 Activation by
Inhibiting PM Association. Based on NMR studies of Epac1 and
X-ray crystallographic studies of Epac2, it has been suggested
that binding of cAMP or 8-pCPT induces an open conformation
of Epac1, allowing the CDC25-HD domain to exert GEF activity
toward Rap1 (8, 21–23). An intramolecular Epac1 FRET probe
(24) stimulated with 8-pCPT induced a similar decrease in
fluorescence energy transfer in cells expressing WT–Epac1 as in
cells expressing the phospho-mimic mutant of Epac1 (Fig. 4A).
These data indicate that phosphorylation of Ser-108 does not
impair the 8-pCPT–induced conformational dynamics of Epac1
or its capacity to activate Rap1 in vitro.
An in vitro fluorescence-based GEF assay with purified Rap1
showed that WT, phospho-mimic, and phospho-deficient Epac1
have a similar capability to catalyze the GDP to GTP exchange
on Rap1 (Fig. 4B). Moreover, addition of GRK2 and ATP as a
phosphate donor did not affect the agonist-induced GEF activity
of WT GST–Epac1 (Fig. 4C).
In cells, 8-pCPT stimulation induces translocation of cytosolic
Epac1 to the PM, where it activates a local Rap1 pool. The re-
sults in Fig. 5A demonstrate that 8-pCPT–induced translocation
of the phospho-mimic mutant of Epac1 (Epac1–S108E) was
significantly reduced compared with WT Epac1. Conversely,
siRNA-mediated knockdown of GRK2 increased the 8-pCPT–
induced PM translocation of WT Epac1 (Fig. 5B; Fig. S8).
Moreover, tethering the phospho-mimic mutant of Epac1 to the
PM by adding a CAAX-motif (ICUE1–PM–S108E) restored
8-pCPT–induced Rap1 activation (Fig. 5C), supporting the
model that phosphorylation of Epac1 by GRK2 at Ser-108
inhibits Epac1-to-Rap1 signaling by preventing its binding to the PM.
GRK2-Mediated Regulation of Epac1 Signaling to Piezo2. In vitro evi-
dence has shown that Epac1 signaling sensitizes Piezo2-mediated
mechanocurrents. To first examine the role of Piezo2 signaling in
CFA-induced mechanical hyperalgesia, we used an antisense
oligodeoxynucleotide (ODN) strategy (7). Intrathecal administration
of Piezo2 antisense ODN (asODN) starting on day 3 after injection
of CFA to target L4–L5 DRG inhibited mechanical hyperalgesia,
but not thermal hyperalgesia (Fig. 6 A and B). A previous study
reported that deletion of Piezo2 from advillin-positive neurons did
not affect mechanical hyperalgesia, as measured 24 h after intra-
plantar injection of CFA. In line with these data, Piezo2 asODN
treatment starting 3 d before CFA injection did not affect me-
chanical hyperalgesia, as measured at 24 h after CFA (Fig. S9).
Next, we investigated the effect of GRK2 on Piezo2-mediated
mechanically evoked currents in HEK cells overexpressing Piezo2
and Epac1 (HEK-PE) in response to the Epac1 agonist 8-pCPT. In
line with a previous study (7), activation of Epac1 by 8-pCPT shifted
the stimulus/response curve to the left, indicating sensitization to
mechanical stimulation. The data in Fig. 6C show that coexpression
of GRK2 (HEK-PE–GRK2) abrogated this sensitizing effect of
Fig. 2. GRK2-mediated regulation of Epac1-to-Rap1 signaling and chronic
pain. (A) Effect of overexpression of kinase dead GRK2 (K220R) on mechanical
hyperalgesia (n = 8 per group). Mice were treated intraplantarly with HSV–
GRK2 or –GFP (empty vector) or HSV–K220R on days 4, 6, 13, and 16 after
intraplantar CFA injection. Changes in 50% paw withdrawal threshold were
monitored over time. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001. Data were analyzed by using two-way ANOVA followed
by Tukey’s post hoc analyses. (B) Rap1 activation in HEK293 (HEK) or HEK293
cells overexpressing GRK2 (HEK–GRK2) cells. Cells transfected with HA–Epac1
were treated with 8-pCPT or vehicle for 20 min followed by a Rap1–GTP pull-
down assay. Bar graph depicts means ± SEM of at least three independent
experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001 (analyzed using t test).
(C) Pull-down of Rap1-GTP from N2A cells or N2A overexpressing GRK2 (N2A–
GRK2). The two right lanes represent two different GRK2-overexpressing
clones. (D) Rap1 activation in N2A–GRK2 or –K220R cells transfected with HA–
Epac1. Cells were stimulated as in B. Data are representative of at least three
independent experiments. Bar graphs represent band density for Rap1–GTP
levels normalized to total Rap1, with Rap1–GTP levels in 8-pCPT–treated control
N2A cells set as 1. ***P < 0.001; ****P < 0.0001.
Fig. 3. GRK2 phosphorylates Epac1 at Ser-108 residue. (A) In vitro phos-
phorylation of Epac1 by GRK2. Visualization of 32P incorporation by auto-
radiography analysis of GST–Epac1 incubated with purified recombinant
GRK2 (50 nM) and [γ32P]ATP (32P) in the absence or presence of 0.01 U/μL
heparin. (B) Representative autoradiogram of 32P incorporation in 25 to
1,000 nM GST–Epac1 incubated with 25 nM GRK2. (C) Alignment of Epac1
sequence surrounding Ser-108 across multiple species. (D) Autoradiogram of
32P incorporation in WT–Epac1 and Epac1–S108A incubated with purified
recombinant GRK2 (50 nM). (E) Rap1 activation in N2A and N2A–GRK2 (NG)
cells transfected with WT–Epac1 (WT), Epac1–S108A (S108A), or Epac1–S108E
(S108E) treated with 8-pCPT. Shown are data representative of three in-
dependent experiments. Bar graph represents band density for Rap1–GTP
levels normalized to total Rap1, with Rap1–GTP levels in 8-pCPT–treated cells
expressing WT Epac1 set as 1. ***P < 0.001; ****P < 0.0001.
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Epac1 stimulation on Piezo2-mediated mechanocurrents. The
maximal mechanically evoked inward current was recorded before
whole cell configuration was lost. At a distension of 8 μm, 8-pCPT
increased this maximal current, and overexpression of GRK2
blocked this effect of the Epac agonist (Fig. 6D). Under baseline
conditions, the stimulus/response curve was similar in HEK and
HEK–GRK2 cells expressing Piezo2 and Epac1.
Discussion
We demonstrate here that Epac1 is required for inflammatory
mechanical hyperalgesia and describe a previously unidentified
mechanism for controlling Epac1 signaling that inhibits in-
flammatory pain in vivo. Specifically, we demonstrate that Rap1
is activated in the DRG of mice with CFA-induced inflammatory
pain, but not in Epac1−/− mice that are protected from me-
chanical hyperalgesia. At the molecular level, we demonstrate
that phosphorylation of Ser-108 in Epac1 by the kinase GRK2
inhibits Epac1-to-Rap1 signaling via preventing agonist-induced
accumulation of Epac1 at the PM. We propose that this molecular
mechanism underlies the protective effect of GRK2 on chronic
inflammatory pain.
The competitive Epac inhibitor ESI-09 (25, 26) inhibits me-
chanical hyperalgesia in the CFA model of inflammatory pain,
and preliminary data indicate that the same is true for the spared
nerve injury model of chronic neuropathic pain. Conversely,
intraplantar administration of the Epac agonist 8-pCPT induces
mechanical hyperalgesia (6, 7, 16, 27). In vitro, ESI-09 inhibits
both Epac1 and Epac2 (27, 28), and there is evidence that both
Epac1 (7) and Epac2 (29) contribute to sensitization of pain-
sensing neurons. We demonstrate here that Epac1−/− mice are
protected from mechanical hyperalgesia in the CFA model of
inflammatory pain and that these mice are also protected against
neuropathic pain (7). Therefore, we propose that Epac1 is the
main target for the pain-relieving effect of ESI-09. Notably, ad-
ministration of ESI-09 does not affect baseline pain sensitivity.
ESI-09 is orally active, and its beneficial effect is maintained for
at least 24 h after a single dose. These properties make ESI-09 an
attractive candidate for clinical translation.
Epac1 acts as a GEF for Rap1 (9, 10), and, in line with a key
role of Epac1 in pain signaling, Rap1–GTP levels were increased
in DRG of WT mice with CFA-induced mechanical hyperalgesia,
whereas we did not detect any change in Rap1–GTP in DRG of
Epac1−/− mice. Thus, although multiple signaling pathways can
activate Rap1, Epac1 is required for Rap1 activation in the DRG in
the context of inflammatory pain.
Earlier studies by us and others have shown that Epac1 protein
levels in the DRG are increased in the CFA model of chronic
inflammatory pain, whereas GRK2 levels are decreased (16, 17,
30–32). In addition, we presented evidence that Epac1-dependent
pain signaling is inhibited by GRK2, but the mechanism remained
to be determined (17). Here, we identify GRK2, to our knowledge,
as the first kinase known to directly phosphorylate Epac1, identify
the site of phosphorylation, and demonstrate that this phosphory-
lation event inhibits Epac1-to-Rap1 signaling. We also demonstrate
that, in vivo, GRK2 kinase activity is required for inhibition of
Epac1-dependent inflammatory mechanical hyperalgesia. These
Fig. 4. Effects of phospho-mimicking Epac1 mutant on Epac1-to-Rap sig-
naling. (A) FRET analyses of 8-pCPT–AM-induced conformational changes of
Epac1 in cells. HEK293 cells were transfected with either WT ECFP–EPAC1–
citrine (WT) or ECFP–Epac1–S108E–citrine (S108E) FRET probes. Cells were
analyzed by flow cytometry after treatment with 30 μM 8-pCPT–AM. Rep-
resentative panels show FRET ratios (405/530) and the percent of YFP-posi-
tive cells with FRET signal. Bar graph shows percent FRET signal decrease in
response to 8-pCPT–AM treatment compared with vehicle-treated cells for
three experiments performed in triplicate. ****P < 0.0001 (two-way
ANOVA). (B) In vitro Epac1 GEF activity using a Rap1b–bodipy–GDP (Rap1b-
bGDP) fluorescence assay. A concentration of 0.2 μM WT GST–Epac1 (WT),
the phospho-deficient mutant GST–Epac1–S108A (S108A), or the phospho-
mimic mutant GST–Epac1–S108EE (S108EE) was incubated with 0.5 μM
fluorescent Rap1b–bGDP and 50 μM GDP in the presence or absence of
25 μM cAMP added at 0 min. Decrease in fluorescence intensity was recorded
as a measure of GEF activity. Bar graph fluorescence signal at 12 min after
cAMP addition. (C) Effect of addition of GRK2 (0.2 μM) and ATP (100 μM) on
in vitro Epac1 GEF activity as assessed in B. No significant differences were
observed between WT GST–Epac1 and the two mutants or after addition of
GRK2 (n = 3).
Fig. 5. Impaired 8-pCPT–induced PM translocation of Epac1–S108E. (A) N2A
were cells transfected with WT YFP–Epac1 (WT) or the phospho-mimic mu-
tant YFP–Epac1–S108E, and stimulated with 8-pCPT–AM for 10 min. (Scale
bars, 25 μm.) *P < 0.05. (B) N2A cells transfected with WT YFP–Epac1 and
siRNA GRK2 or scrambled siRNA (scr) and stimulated with 8-pCPT–AM as in
A. Shown are representative images. Bar graph represents mean percentage
of cells with Epac1 accumulation in the PM in response to 8-pCPT as de-
termined in three independent experiments each including >50 cells per
condition. (Scale bars, 25 μm.) *P < 0.05. (C) Rap1 activation in N2A cells
transfected with WT Epac1 (ICUE1-WT) or Epac1–S108E (ICUE1-S108E) (Left)
or with PM-tagged WT Epac1 (ICUE1-PM-WT) or PM-tagged Epac1–S108E
(ICUE1-PM-S108E) (Right), and stimulated with 8-pCPT–AM for 10 min.
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findings collectively support a model in which GRK2-mediated
phosphorylation of Epac1 prevents Rap1 activation and thereby
reduces inflammatory mechanical hyperalgesia.
Epac1-to-Rap1 signaling is a multistep process involving cAMP-
induced liberation of Epac1 from a closed, autoinhibitory to an
open conformation, allowing binding of Rap1 to the catalytic
CDC25-HD domain and GEF activity (8, 11, 24, 33, 34). Our
FRET analysis revealed that in cells, the Epac1 mutant that
mimics phosphorylation by GRK2 (Epac1–S108E) undergoes
normal agonist-induced conformational changes. In addition,
in vitro experiments showed that the ability of WT Epac1 in the
presence or absence of GRK2 and of phospho-mimic Epac1 to
function as a Rap1–GEF did not differ. Nevertheless, phos-
phorylation by GRK2 markedly reduces Epac1-mediated Rap1
activation in cells. We propose that the GRK2-mediated inhi-
bition of Rap1 activation results from impaired agonist-induced
PM accumulation of phosphorylated Epac1. This model is sup-
ported by the reduced 8-pCPT–induced PM accumulation of the
phospho-mimic mutant of Epac1, whereas reducing cellular GRK2
levels increases PM accumulation of WT Epac1. Moreover, sig-
naling of the phospho-mimic mutant of Epac1 to Rap1 normalized
when it was targeted to the PM by addition of a −CAAXmotif. PM
phosphatidic acid (PA) functions as the anchor for activated Epac1
in response to cAMP, and this binding requires Arg-82 in the DEP
domain of Epac (11, 35, 36). PA-dependent PM anchoring of DEP
domain-containing proteins also requires penetration of hydro-
phobic amino acids into the acyl layer of the PM (37). Given our
results and the amino acid sequence of the region surrounding Ser-
108 in Epac1, it is conceivable that the negative charge added by
phosphorylation of Ser-108 reduces its hydrophobicity and intro-
duces negative charges, thereby inhibiting PM accumulation of
phosphorylated Epac1.
It remains to be determined which downstream signaling
pathways are responsible for the increased mechanical sensitivity
of pain-sensing neurons downstream of Epac1-to-Rap1 signaling.
A recent study has shown that Epac1 activation increases
mechanocurrents mediated by the mechanosensitive channel
Piezo2 (7). We show that inhibition of Epac1 signaling by over-
expression of GRK2 prevents Epac-mediated sensitization of
Piezo2-mediated mechanocurrents. Moreover, decreasing DRG
Piezo2 levels in vivo by using asODN treatment protected
against neuropathic pain (7) and, as shown here, inhibited the
late phase of CFA-induced mechanical hypersensitivity. Consistent
with a previous study (38), however, we did not detect a role for
Piezo2 in CFA-induced mechanical hyperalgesia as measured 24 h
after CFA administration. These findings indicate that the early
(<24 h) and late phases of CFA-induced mechanical hyperalgesia
are mediated via different mechanisms. Indeed, a recent study
showed that only the early phase of CFA-induced hyperalgesia
(<5 h) was reduced by the PKA inhibitor PKAi, whereas in-
hibition of the Epac1 target PKC-e reduced CFA-induced
hyperalgesia during the later phase (39). In addition, there is
evidence that CFA-induced inflammation leads to a shift in cAMP
signaling from a PKA to a PKC-e–mediated pathway (40). On
the basis of these earlier findings, we propose that Epac1-
mediated sensitization of neuronal Piezo2 contributes to the later
phase of CFA-induced hyperalgesia, whereas PKA-mediated Piezo2-
independent pathways are operative early after CFA injection.
Epac1 signaling could contribute to pain via Piezo2-independent
pathways as well. For example, Epac activation leads to closure
of potassium channels in pancreatic β cells (41), whereas many
antinociceptive drugs work by opening potassium channels in
sensory neurons (42). In addition, Piezo2 is expressed in non-
neuronal cells, including astrocytes and endothelial cells (43, 44),
and we cannot exclude that Piezo2 asODN treatment inhibits CFA-
induced hyperalgesia via reducing Piezo2 levels in these cells.
In conclusion, we propose that Epac1 plays a critical role in
inflammatory pain via a mechanism involving PM Epac1-to-
Rap1 signaling and sensitization of Piezo2-mediated mechano-
currents. We also propose that constitutive GRK2-mediated
phosphorylation of Epac1 on Ser-108 represents an essential
control mechanism for cAMP–Epac1-dependent functions in-
cluding mechanical hyperalgesia. Epac1 is known to contribute
to multiple processes within and outside the nervous system,
including neuronal excitability, long-term potentiation, axon
guidance, muscle excitation and contraction, cell migration and
adhesion, learning, regulation of inflammation, and energy ho-
meostasis (15, 45–47). It is likely that the GRK2-mediated phos-
phorylation of Epac1 leading to reduced Epac1-to-Rap1 signaling
that we uncovered here regulates these processes as well.
Materials and Methods
We used Epac1−/−mice (17, 48) and their WT control littermates in a C57BL/6
background at an age of 12–14 wk. All procedures were performed in ac-
cordance with National Institutes of Health Guide for the Care and Use of
Laboratory Animals (49) and were approved by the Institutional Animal Care
and Use Committee of the University of Texas MD Anderson Cancer Center.
Mechanical hyperalgesia was measured by using von Frey hairs, and heat
withdrawal latency times were determined by using the Hargreaves (IITC
Life Science). The 8-pCPT and 8-pCPT–acetoxymethyl ester (AM) (Axxora)
were dissolved in DMSO. ESI-09 was dissolved in ethanol (5 mg/mL) followed
by dilution in corn oil (1:1) and speed vacuum to remove ethanol. GTP-
bound Rap1 was pulled down by using Ral-GDS beads (18), and Rap1 was
quantified by Western blotting. Currents were recorded as described (7) by
using Axopatch 200B and Multiclamp 700 amplifiers (Axon Instruments, Molec-
ular Devices) from HEK293 cells. In vitro Epac1 GEF activity was measured by
using a similar protocol as described (28). Cells were imaged by using a Delta-
vision Deconvolution Microscope (Applied Precision) or a SPE Leica Confocal
Microscope (LeicaMicrosystems) at 37 °C. Data are expressed as mean ± SEM and
were analyzed by using two-tailed Student’s t test or one- or two-way ANOVA.
Fig. 6. Role of Piezo2 in CFA-induced mechanical hyperalgesia. (A) Effect of
asODN against Piezo2 on CFA-induced mechanical hyperalgesia. Treatment,
P < 0.0001; interaction, P < 0.0001 (two-way ANOVA). *P < 0.1; **P < 0.01;
***P < 0.001; ****P < 0.0001 (Bonferroni posttest). (B) Effect of an asODN
against Piezo2 on CFA-induced thermal hyperalgesia. For A and B, Piezo2 or
scrambled asODNs were administered intrathecally on days 1, 2, 3, 5, 6, 7,
and 8 after CFA injection. (C) Mechanically evoked currents in HEK cells
transfected with Piezo2 and YFP–Epac1 overexpressing GRK2 (HEK-PE-GRK2)
(n = 22–26 cells) or control HEK–PE cells (n = 20–22 cells). The 8-pCPT or bath
solution was added, and cells were voltage-clamped at −60 mV in a whole-
cell configuration. Mechanically evoked currents were elicited by increasing
displacement of the cell membrane in 1-μm increments. **P < 0.01; ***P <
0.001. (D) Peak current elicited by the largest mechanical stimulus before
whole-cell configuration was lost. **P < 0.01.
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